Literature DB >> 18242090

Natural history of CMT1A including QoL: a 2-year prospective study.

L Padua1, D Pareyson, I Aprile, T Cavallaro, A Quattrone, N Rizzuto, G Vita, P Tonali, A Schenone.   

Abstract

The Italian CMT study group performed a multicentre, multidimensional, longitudinal 2-year follow-up study using validated measurements of neurological impairment, disability and quality of life. The aim of the study was to evaluate the natural history of clinical features, disability and QoL in patients with CMT1A. On clinical examination, CMT1A patients showed a significant reduction in muscle strength and sensory function during the 2-year follow-up period. However, there was no worsening of QoL or disability, nor was depression observed. The discrepancy between the evolution of clinical features and the evolution of QoL and disability may be due to the development of compensatory strategies that help patients cope with the slow progression of the disease. Our observations provide information which may be useful when designing clinical trials in CMT.

Entities:  

Mesh:

Year:  2008        PMID: 18242090     DOI: 10.1016/j.nmd.2007.11.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  13 in total

Review 1.  Quality of life in rare genetic conditions: a systematic review of the literature.

Authors:  Julie S Cohen; Barbara B Biesecker
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  Natural history of Charcot-Marie-Tooth 2: 2-year follow-up of muscle strength, walking ability and quality of life.

Authors:  Luca Padua; D Pareyson; I Aprile; T Cavallaro; D A Quattrone; N Rizzuto; G Vita; P Tonali; A Schenone
Journal:  Neurol Sci       Date:  2009-12-17       Impact factor: 3.307

3.  Evolution of Charcot-Marie-Tooth disease type 1A duplication: a 2-year clinico-electrophysiological and lower-limb muscle MRI longitudinal study.

Authors:  Ana L Pelayo-Negro; Elena Gallardo; Antonio García; Pascual Sánchez-Juan; Jon Infante; José Berciano
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

4.  Efficacy of focal mechanic vibration treatment on balance in Charcot-Marie-Tooth 1A disease: a pilot study.

Authors:  Costanza Pazzaglia; F Camerota; M Germanotta; E Di Sipio; C Celletti; L Padua
Journal:  J Neurol       Date:  2016-05-13       Impact factor: 4.849

5.  Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A.

Authors:  Nicholas E Johnson; Chad R Heatwole; Michele Ferguson; Janet E Sowden; Shanie Jeanat; David N Herrmann
Journal:  J Clin Neuromuscul Dis       Date:  2013-09

6.  Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children.

Authors:  Emanuela Pagliano; Isabella Moroni; Giovanni Baranello; Anita Magro; Alessia Marchi; Sara Bulgheroni; Maurizio Ferrarin; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

7.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

Review 8.  Charcot-Marie-Tooth disease, psychiatric indicators and quality of life: a systematic review.

Authors:  Joana L C Cordeiro; Wilson Marques; Jaime E C Hallak; Flávia L Osório
Journal:  ASN Neuro       Date:  2014-05-27       Impact factor: 4.146

9.  Changes of gait pattern in children with Charcot-Marie-Tooth disease type 1A: a 18 months follow-up study.

Authors:  Maurizio Ferrarin; Tiziana Lencioni; Marco Rabuffetti; Isabella Moroni; Emanuela Pagliano; Davide Pareyson
Journal:  J Neuroeng Rehabil       Date:  2013-07-02       Impact factor: 4.262

Review 10.  PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.

Authors:  Barbara W van Paassen; Anneke J van der Kooi; Karin Y van Spaendonck-Zwarts; Camiel Verhamme; Frank Baas; Marianne de Visser
Journal:  Orphanet J Rare Dis       Date:  2014-03-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.